Latest Announcements
Ladenburg Thalmann Acts as Financial Advisor to Board of Trustees of Vertical Capital Income Fund in New Investment Advisory Agreement with Carlyle
Transaction Information Ladenburg Thalmann & Co. Inc. served as financial advisor to Board of Trustees of Vertical Capital Income Fund (VCIF) in a transaction in which VCIF signed a new investment advisory...
Ladenburg Serves Exclusive Roles in Completion of Ra Medical Systems Merger with Catheter Precision and $9.3 Million Financing
Ladenburg acted as the Financial Advisor in the Merger and Exclusive Warrant Inducement Agent and Placement Agent in the $9.3 Million Equity Financing Merger Ra Medical Systems, Inc. (NYSE American: RMED)...
Ladenburg Acts as Exclusive Placement Agent in $10 Million Financing for Midatech Pharma and Exclusive Advisor in Merger Between Bioasis Technologies and Midatech
Transaction Information Merger Bioasis Technologies Inc. (TSX.V:BTI), a multi-asset rare and orphan disease biopharmaceutical company entered into a definitive agreement with Midatech Pharma plc...
Ladenburg Thalmann Acts as Sole Book-Running Manager and Exclusive Placement Agent for $32 Million Offering for NeuroBo Pharmaceuticals, Inc.
Transaction Information NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full...
Ladenburg Acts as Exclusive Warrant Solicitation Agent in $3.12 Million Offering for Kiora Pharmaceuticals, Inc.
Transaction Information Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced it has entered into warrant inducement offer letters to raise $3.12 million in gross proceeds from the exercise of 654,609 Class A...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to GBS Inc. in its Acquisition of Intelligent Fingerprinting
Transaction Information GBS Inc. (Nasdaq: GBS) announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In...
Ladenburg Thalmann Acts as Sole Book-Running Manager for Nuwellis, Inc. in its $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
Transaction Information Nuwellis, Inc. (Nasdaq: NUWE) announced the closing of an underwritten public offering of units with gross proceeds of approximately $11.04 million, which includes the full exercise of...
Ladenburg Thalmann Acts as Manager for Rhythm Pharmaceuticals, Inc. in its $124.8 Million Public Offering
Transaction Information Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM) announced the closing of its public offering of 4,800,000 shares of its common stock at a public offering price of $26.00 per share on September...
Ladenburg Acts as Exclusive Placement Agent and Exclusive Warrant Solicitation Agent in $5.3 Million Offering for NovaBay Pharmaceuticals, Inc.
Transaction Information NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private...
Ladenburg Thalmann Acts as Sole Book-Running Manager for Palisade Bio, Inc. in its $13.8 Million Underwritten Public Offering
Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Phosphorex's Majority Acquisition by Ampersand Capital Partners
Transaction Information Phosphorex Inc. announced a majority acquisition by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Phosphorex...
Ladenburg Thalmann Acts as Exclusive Warrant Inducement Agent in Ra Medical's (RMED) $6.2M Warrant Repricing and Announces Strategic Merger Plans with Catheter Precision Inc.
Transaction Information Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") announced a reduction in the exercise price of all existing warrants that were issued in the February 2022...